Personalized Antifibrotic Therapy in CKD Progression
2024
Personalized Antifibrotic Therapy in CKD Progression
publication
Evidence: moderate
Author Information
Author(s): Delrue Charlotte, Eisenga Michele F., Delanghe Joris R., Speeckaert Marijn M.
Primary Institution: Ghent University Hospital
Hypothesis
The review emphasizes the need for tailored antifibrotic medications for chronic kidney disease (CKD) treatment.
Conclusion
Personalized antifibrotic therapies targeting key pathways can potentially improve outcomes in CKD patients.
Supporting Evidence
- Chronic kidney disease (CKD) is a progressive disease that can lead to end-stage kidney disease.
- Current medications do not stop or reverse fibrosis, highlighting the need for personalized treatments.
- Precision medicine can improve therapeutic efficacy while decreasing adverse effects.
Takeaway
This study talks about how doctors can make special medicines for people with kidney problems to help them get better.
Methodology
The review discusses various antifibrotic therapies and their mechanisms in the context of CKD.
Limitations
The review does not provide new clinical trial data but summarizes existing literature.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website